By embedding environmental, social and governance (ESG) topics into core business strategy and operations, Novartis aims to build trust with society and deliver long-term value to stakeholders. In February, the company released its first Novartis in Society Integrated Report 2021, marking a new approach to reporting which describes how it creates value for stakeholders through its purpose of reimagine medicine to improve and extend people’s lives. As a case in point, in 2021, Novartis’ medicines reached 766 million patients pf which 56.2 patients were reached through its various access-to-medicine approaches. This report is intended for all Novartis stakeholders, and it complies with specific requirements of investors and ESG professionals.